Prostate cancer is the most common cancer affecting men and the leading cause of cancer deaths in men of all races in the United States. More than 12% of men will have prostate cancer at some point in their lifetime, with an average age of diagnosis at 66.
Although prostate cancer has a high survival rate because of the slow progression of the disease, compared to other cancers, many available treatments often come with long-term complications that could impact on the quality of life of survivors.
Available treatments include chemotherapy, hormonal therapy, radiation therapy, and surgery, which are offered depending on the severity or grade of the cancer. Common problems associated with conventional treatment may include erectile problems, urinary incontinence, ineffective treatment, and recurrence of the tumor.
At the Center for Prostate Cancer in New York City, Dr. Ashutosh Tewari is leading the way in effective prostate cancer treatments with world-class therapy options offered in a comprehensive approach. Dr. Tewari and his team use state-of-the-art evaluation techniques for early diagnosis, surveillance, and treatment of prostate cancer.
Dr. Tewari leverages three critical diagnostic approaches for all patients with prostate cancer: Precision Urology, Genomic Testing, and Multiparametric MRI. These unique diagnostic techniques deliver a personalized approach to evaluating patients with prostate cancer, offering patients the most appropriate therapies based on these diagnostic data.
Consequently, Dr. Tewari and his team deliver individualized treatment recommendations that will offer the most effective treatment outcome, rather than providing generic treatments or trial-and-error approaches to prostate cancer treatments.
Precision Urology
The Precision Urology™ was designed by Dr. Tewari and his team to include multiple variables in evaluating and treating patients with prostate cancer. This tool integrates machine learning-enabled methods to offer precise diagnostic data about each patient.
Precision Urology integrates several tools, including the 4KScore, PSA levels, and other metrics to determine the need for prostatic intervention. The Center for Prostate Cancer uses state-of-the-art molecular diagnostic tests, such as Prolaris, Oncotype Dx, ConfirmMDx, Precise MD, and Decipher in its initial risk assessment of patients to determine the most appropriate diagnostic or treatment intervention needed.
3 Tesla Multiparametric MRI
The 3 Tesla Multiparametric Magnetic Resonance Imaging (mp-MRI) is an innovative, state-of-the-art, non-invasive imaging technique that offers cutting edge prostate diagnostic and staging data.
The 3-tesla multiparametric MRI is superior to older, less powerful MRI machines as it gives adequate detail about tissues and clearly differentiates between benign and cancerous changes within tissues. The 3-tesla multiparametric MRI significantly enhances image quality, enabling easy staging of the tumor.
This non-invasive test has revolutionized prostate cancer diagnosis and treatment, driving quick detection of cancer cells within the prostate before even considering an invasive procedure, such as prostate biopsy.
Genomics Testing
Genomics testing is at the core of personalized cancer treatment as it uses clear genomic and molecular data to map patients to the right treatment strategies for them. This eliminates the trial-and-error treatment approach, which involves generic treatment algorithms until an effective treatment is found.
Using cutting-edge DNA sequencing technologies, Dr. Tewari and his team are able to identify various prostate cancer types and determine which treatment is suitable for which one, and which treatment option is most appropriate for each patient.
Genomic testing also ensures rapid identification of aggressive cancer types and patients at risk of poor treatment outcomes or recurrence of disease.
This tripod diagnostic process ensures an easy and quick evaluation of patients with prostate cancer and gives the team adequate detail about a patient’s prostate tumor before the treatment process begins.
Innovative Treatment Options for Prostate Cancer by Dr. Tewari
Dr. Tewari offers innovative surgical treatments for patients with prostate cancer. Leveraging the Da Vinci robotic system, Dr. Tewari has developed novel surgical techniques that optimize recovery after prostate surgery and minimize complications known to conventional therapies.
The Da Vinci robotic system is a revolutionary surgical approach to prostate cancer treatment, using a robotic platform that delivers precise incisions and a minimally invasive approach to prostate surgery. Translating the surgeon’s hand movements into precise micro-movements of the robotic system, the Da Vinci procedure delivers a safe and effective surgical option for prostate cancer treatment.
A pioneer of da Vinci® robotic surgery for prostate cancer, Dr. Tewari has performed more than 7,000 robotic prostatectomies (surgery to remove the entire prostate), making him one of the most skilled and experienced robotic surgeons in the world. While at Henry Ford, Dr. Tewari was part of the team that performed the first robotic radical prostatectomy in the United States.
The ART™ Surgical Technique
The Robotic Prostate Surgery approach used by Dr. Tewari is known as ART™ (Advanced Robotic Technique) prostatectomy. This is a highly effective individualized surgical approach that minimizes complications and optimizes treatment outcomes. Developed by Dr. Tewari and his team, the ART™ has been refined over the years to become an effective approach to prostate cancer treatment around the world.
The principle of the ART™ technique is the delicate removal of the prostate from the top of the nerve hammock with maximal clearance for preserving sexual and urinary function. The nerves are not disturbed, and nerve oxygenation is monitored during this phase of the technique, so these preserved nerves are intact and healthy.
Dr. Tewari and his team have also modified the technique into what is known as the Hood Technique, which is aimed at preventing urinary leakage following treatment. This expedites continence recovery following prostate surgery as it creates minimal disruption to urination, as opposed to conventional prostate surgery techniques.
The exciting thing about this surgical approach is that patients get discharged and return home 24 hours after the surgery.
Nerve-Preserving Technique: NeuroSAFE™
To optimize results even further, Dr. Tewari has developed, in collaboration with the University of Hamburg, the NeuroSAFE™ technique, which incorporates pre-operative MRI based- planning for cancer removal. Using this technique, the entire nerve margin is evaluated by the pathologist in real time so that more nerves can be saved, while giving us the ability to ensure any additional cancer is seen before finishing the operation.
This ensures minimal or no nerve dysfunction following surgery, preserving nerve functions such as erection and urination.
Other Treatment Options
Dr. Tewari and his team also offer cutting-edge treatment options that have proven to be effective and superior, including focal therapy and immunotherapy.
The Center’s Prostate Cancer Immunotherapy Program leverages a personalized approach that identifies immunotherapies that are suitable for the patient’s specific prostate cancer type. Traditionally, immunotherapy uses the patient’s own immune system to fight off cancer cells, eliminating many complications and side effects associated with conventional chemotherapy and radiation therapy.
Dr. Tewari and his team at the Center for Prostate Cancer are truly revolutionizing prostate cancer care. With more than 25 years treating prostate cancer and after more than 9000 robotic prostate cancer surgeries and hundreds of peer-reviewed publications in the field, Dr. Tewari and the team at the Center for Prostate Cancer are game changers in prostate cancer diagnosis and treatment.
We recommend Dr. Ash Tewari as a global leader in prostate cancer surgery. Serving as the Chairman of Urology at the Icahn School of Medicine at Mount Sinai Hospital, New York City, Dr. Tewari stands out as a prostate cancer robotic surgeon leader. With over 25 years of expertise in robotic-assisted prostate surgery, he has successfully performed over 9,000 procedures.
In addition, he has contributed to the scientific community with over 250 peer-reviewed articles, book chapters, and textbooks on prostate cancer and robotic surgery. Renowned for his expertise in sexual-function nerve-sparing prostate cancer surgery - Dr. Tewari is a pioneer in innovative treatments for intermediate to aggressive cancers. Furthermore, he leads numerous pivotal clinical trials in this field.
For inquiries or to connect with Dr. Tewari's team Prostate Cancer Center NYC - Dr. Ashutosh Tewari
